2026 NPPES data Pharmacist NPI 1669013991
Verify on CMS →

MARYLEXIS ADIR

Pharmacist in SARASOTA, Florida. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
135
Medicare Part D claims · 132 beneficiaries · Pharmacist avg: 135
Generic prescribing
0%
generic claims · 100% brand-name · higher generic rates reduce patient out-of-pocket costs
What the federal data reveals: MARYLEXIS ADIR is a Pharmacist ([object Object]) practicing in SARASOTA, Florida with a Medicare Part D prescribing footprint of 135 claims across 132 beneficiaries — 100% brand-name prescribing .

What stands out: MARYLEXIS ADIR filed 135 Medicare Part D claims in 2023 across SARASOTA, Florida. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

MARYLEXIS ADIR at a glance

Quality data not reported

NPI registry status

Active

Issued 10/08/2019

NPI 1669013991

Primary specialty

Pharmacist

High-volume

290,447 US NPIs in this specialty

Medicare Part D claims

135 0% vs specialty avg

2023 prescription claims

Specialty avg: 135

Specialty distribution in Florida

How Pharmacist compares to other specialties among Florida providers

Florida providers

Pharmacist share within Florida

1. Pharmacist42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Pharmacist share within Florida

Specialty board-certification context

Estimated specialty board-certified rate — Pharmacist (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Pharmacist ABMS/AOA estimate

Est. board-certified rate (Pharmacist) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Pharmacist) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MARYLEXIS ADIR is a Pharmacist provider practicing in SARASOTA, Florida, according to the CMS National Plan and Provider Enumeration System (NPPES). NPI: 1669013991. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

MARYLEXIS ADIR appears in the CMS NPPES registry as a Pharmacist provider at 2875 UNIVERSITY PKWY, SARASOTA, FL, 34243, with a listed phone of (941) 358-5250. NPI 1669013991 was issued on 10/08/2019. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ADIR most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 135 prescription claims written by this provider, covering 132 Medicare beneficiaries and totaling roughly $37K in drug spend, split 100% brand-name and 0% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Pharmacist is a high-volume specialty nationwide, with 290,447 enrolled providers across 56 states and an average of 135 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

2875 UNIVERSITY PKWY
SARASOTA, FL 34243

Provider Details

NPI 1669013991
Specialty Pharmacist
Gender Female
NPI Issued 10/08/2019

License & disciplinary context — Florida FLDOH 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~75K Florida medical licensees in 2023 — they are NOT specific to MARYLEXIS ADIR. To verify MARYLEXIS ADIR's current license status, search the FLDOH public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

480
Total board actions, Florida 2023
Across 467 cases
6.40
Actions per 1,000 licensees
Florida statewide rate
monetary fine
Most common action type
138 cases

FLDOH publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Florida disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Brand-heavy

MARYLEXIS ADIR — brand share 100.0%
Specialty average (est.)

100% brand-name claims vs 0% generic, on 135 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

135
Total Claims
$37K
Total Drug Cost
132
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
136
Total Day Supply
194
Brand vs Generic
100% brand / 0% generic
Brand Drug Cost
$37K
Generic Drug Cost
$0

Patient Demographics

Average Patient Age
77.3 years
Avg HCC Risk Score
1.04
Gender Split
62% female / 38% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Arexvy
Rsvpref3 Antigen/As01e/Pf
85
Shingrix
Varicella-Zoster Ge/As01b/Pf
41

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Pharmacist Overview

How MARYLEXIS ADIR fits within the Pharmacist landscape nationally.

290,447
Pharmacist Providers in US
56
States with Pharmacist
135
Avg Claims per Provider

MARYLEXIS ADIR's 135 claims are below the specialty average of 135.

Nearby Pharmacist Providers in Florida

Other clinicians with the same primary specialty enrolled in Florida, drawn from the same CMS NPPES roster as ADIR.

Compare Pharmacist nationally: see state-by-state distribution →

Frequently Asked Questions

What is MARYLEXIS ADIR's specialty?
MARYLEXIS ADIR specializes in Pharmacist and practices in SARASOTA, Florida.
How much does MARYLEXIS ADIR prescribe under Medicare Part D?
In 2023, MARYLEXIS ADIR wrote 135 Medicare Part D claims totaling $37K in drug costs for 132 beneficiaries.
Where is MARYLEXIS ADIR located?
MARYLEXIS ADIR is located at 2875 UNIVERSITY PKWY, SARASOTA, FL, 34243. Phone: (941) 358-5250.
What is MARYLEXIS ADIR's NPI number?
MARYLEXIS ADIR's National Provider Identifier (NPI) is 1669013991, issued on 10/08/2019.
Does MARYLEXIS ADIR prescribe more brand-name or generic drugs?
MARYLEXIS ADIR's prescribing is 100% brand-name and 0% generic drugs by claim count, with $37K in brand drug costs.
How many Pharmacist providers are there in the US?
There are 290,447 Pharmacist providers across 56 states in the US. The average Pharmacist provider writes 135 Medicare Part D claims per year.
What drugs does MARYLEXIS ADIR prescribe most often?
Based on 2023 Medicare Part D data, MARYLEXIS ADIR's most frequently prescribed drugs include Arexvy, Shingrix. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MARYLEXIS ADIR accept Medicare?
MARYLEXIS ADIR appears in CMS Medicare data with 135 Part D claims and 132 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MARYLEXIS ADIR's credentials?
MARYLEXIS ADIR's NPI is 1669013991. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology